Keywords: هیپرکلسترولمی خانوادگی heterozygous; PCSK9 inhibitor; Alirocumab; Expanded use; Heterozygous familial hypercholesterolemia; Coronary heart disease; LDL-C; Statin intolerance; ODYSSEY;
مقالات ISI هیپرکلسترولمی خانوادگی heterozygous (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Familial hypercholesterolemia; Children; Inflammation; Monocytes; Lymphocytes; Atherosclerosis; CRP; C reactive protein; CVD; cardiovascular disease; FH; heterozygous familial hypercholesterolemia; HDL-C; high-density lipoprotein cholesterol concentration
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Statins; Treatment changes; Adherence; Persistence;
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Anacetrapib; Low-density lipoprotein cholesterol; High-density lipoprotein cholesterol; Cholesteryl ester protein inhibitor; Heterozygous familial hypercholesterolemia;
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; LDL cholesterol; Cardiovascular risk; Hypercholesterolemia; Hyperlipidemia;
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Atorvastatin; Children; Adolescents; Tanner stage; Low-density lipoprotein cholesterol;
Keywords: هیپرکلسترولمی خانوادگی heterozygous; ASCVD; atherosclerotic cardiovascular disease; CHD; coronary heart disease; CVD; cardiovascular disease; CYP; cytochrome; EAS; European Atherosclerosis Society; FDA; Food and Drug Administration; FH; Familial hypercholesterolemia; GOF; gain of function; H
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Diabetes mellitus; Statins; Heterozygous familial hypercholesterolemia; Familial combined hyperlipidemia;
LDL-cholesterol target achievement in patients with heterozygous familial hypercholesterolemia at Groote Schuur Hospital: Minority at target despite large reductions in LDL-C
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; LDL-Cholesterol; Target achievement; Cardiovascular disease; Statins; Ezetimibe; PCSK9 inhibitors;
LDL Receptor Gene-ablated Hamsters: A Rodent Model of Familial Hypercholesterolemia With Dominant Inheritance and Diet-induced Coronary Atherosclerosis
Keywords: هیپرکلسترولمی خانوادگی heterozygous; LDL receptor; Golden Syrian hamster; Hyperlipidemia; Atherosclerosis; CRISPR/Cas9; ApoB; apolipoprotein B; ApoE; Apolipoprotein E; CETP; cholesteryl ester transfer protein; CAD; coronary artery disease; CD; chow diet; CHD; cardiovascular heart diseases; C
Clinical Genetic Testing for Familial Hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; cascade testing; consensus statement; familial hypercholesterolemia; genetic counseling; genetic testing; ACMG; American College of Medical Genetics and Genomics; APOB; apolipoprotein B; CAD; coronary artery disease; DLCNC; Dutch Lipid Clinic Network Diag
Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Coronary mortality; Cancer mortality; Dutch lipid clinic network score;
The different relations of PCSK9 and Lp(a) to the presence and severity of atherosclerotic lesions in patients with familial hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Proprotein convertase substilisin/kexin type 9; Lipoprotein (a); Atherosclerotic lesions; Heterozygous familial hypercholesterolemia;
Heterozygous familial hypercholesterolemia presenting as chylomicronemia syndrome
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Chylomicronemia syndrome; Heterozygous familial hypercholesterolemia; Genetics; Triglyceride rich lipoproteins; PCSK9 inhibitors;
Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Coronary atherosclerosis; Intravascular ultrasound; Proprotein convertase subtilisin/kexin type 9;
Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Low-density lipoprotein cholesterol; Cardiovascular risk; PCSK9 inhibitors; Alirocumab; Evolocumab;
Postprandial Changes in Chemokines Related to Early Atherosclerotic Processes in Familial Hypercholesterolemic Subjects: A Preliminary Study
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Chemokines; Heterozygous familial hypercholesterolemia; Unsaturated fat; Oral fat load test; Postprandial state
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Apo; apolipoprotein; ASCVD; atherosclerotic cardiovascular disease; CKD; chronic kidney disease; CV; cardiovascular; HDL-C; high-density lipoprotein cholesterol; HeFH; heterozygous familial hypercholesterolemia; LDL-C; low-density lipoprotein cholesterol;
Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Children; Heterozygous familial hypercholesterolemia; Low-density lipoprotein cholesterol; Rosuvastatin; Safety; Tolerability;
Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Diagnosis; Familial hypercholesterolemia; Heterozygous familial hypercholesterolemia; Prevention; Therapy
Los polimorfismos del gen LRP1 se asocian al riesgo prematuro de enfermedad cardiovascular en pacientes con hipercolesterolemia familiar
Keywords: هیپرکلسترولمی خانوادگی heterozygous; ECVp; enfermedad cardiovascular prematura; HFh; hipercolesterolemia familiar heterocigótica; LRP1; proteÃna 1 relacionada con el receptor de lipoproteÃnas de baja densidad; SNP; polimorfismo de un solo nucleótido; Enfermedad cardiovascular; Polimorfis
Las concentraciones de Apo-B100 en los pacientes con hipercolesterolemia familiar se asocian a una mayor rigidez arterial
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Rigidez arterial; Hipercolesterolemia familiar heterocigota; Índice de aumento; Apolipoproteína-B100; Grosor íntima-media carotídeoArterial stiffness; Heterozygous familial hypercholesterolemia; Augmentation index; Apolipoprotein-B100; Intimae-media thick
Colesevelam Hydrochloride: Efficacy and Safety in Pediatric Subjects with Heterozygous Familial Hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; AE; Adverse event; cIMT; Carotid intima-media thickness; HCl; Hydrochloride; HDL; High-density lipoprotein; heFH; Heterozygous familial hypercholesterolemia; LDL; Low-density lipoprotein; LOCF; Last observation carried forward; NCEP; National Cholesterol
The Type of LDLR Gene Mutation Predicts Cardiovascular Risk in Children with Familial Hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; aIMT; Aorta intima-media thickness; Apo B; Apolipoprotein B; BMI; Body mass index; CI; Confidence interval; cIMT; Carotid intima-media thickness; FH; Familial hypercholesterolemia; HDL-C; High-density lipoprotein cholesterol; heFH; Heterozygous familial h
Efficacy and Safety of Coadministration of Ezetimibe and Simvastatin in Adolescents With Heterozygous Familial Hypercholesterolemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; ezetimibe; simvastatin; heterozygous familial hypercholesterolemia; efficacy; safety; pediatricAAP, American Academy of Pediatrics; apo B, apolipoprotein B; CPK, creatinine phosphokinase; FH, familial hypercholesterolemia; HDL-C, high-density lipoprotein
Evidence that non-lipid cardiovascular risk factors are associated with high prevalence of coronary artery disease in patients with heterozygous familial hypercholesterolemia or familial combined hyperlipidemia
Keywords: هیپرکلسترولمی خانوادگی heterozygous; Heterozygous familial hypercholesterolemia; Familial combined hyperlipidemia; Lipids; Cardiovascular risk factors; Coronary artery disease;